Korro Bio vs Cartesian Therapeutics
KRRO and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRRO and RNAC compare
Korro Bio and Cartesian Therapeutics are about the same size, with market caps of $211M and $208M.
Korro Bio keeps more of each dollar of sales as profit, with a net margin of −8214% compared with −12435% at Cartesian Therapeutics.
Korro Bio scores higher on the StockData Score (5 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRRO | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $211M | $208M |
| Share price | $14.31 | $6.88 |
| Change, 1 year | −56.4% | −5.0% |
| Change, 5 years | −95.2% | −92.9% |
| Beta (5Y) | 2.09 | 1.40 |
| Employees | 58 | 75 |
| StockData Score | ||
| Total score | 5 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 163× (better) | 203× |
| FCF yield | −30.3% (better) | −43.2% |
| Growth | ||
| Revenue growth (TTM) | −82.5% | – |
| Revenue growth, 5Y average | −29.6% (better) | −30.0% |
| Profitability | ||
| Operating margin | −8467% (better) | −15541% |
| Net margin | −8214% (better) | −12435% |
| FCF margin | −4944% (better) | −8770% |
| Financial health | ||
| Current ratio | 7.30 | 8.38 (better) |
| Altman Z-score | −3.71 (better) | −5.09 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 29.3% |
| Held by insiders | 27.5% | 55.7% |
| Insider net buying, 12 months | $16.0M (better) | −$52.9K |
| Short interest, % of float | 16.4% | 14.3% |
Go deeper
- KRRO stock overview
- KRRO income statement
- KRRO valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.